0210229991
0210229910
0210229925
0210229980
0210229990
ICNA0210229991EA
1644
EUR
InStock
ICNA0210229991
ICNA0210229910
ICNA0210229925
ICNA0210229980
ICNA0210229990
Méthotrexate ≥98%, poudre orange USP
Méthotrexate
Folic Acid antagonist; structurally similar to folic acid. Methotrexate is a mixture of 4-amino-10-methylfolic acid and closely related compounds.
A potent anticancer agent. Blocks DNA synthesis by blocking the production of tetrahydrofolate cofactors required for the synthesis of thymidine. Methotrexate is actively transported into cells by the folate transporter. In the cell, it is converted to a high molecular weight polyglutamate metabolite by folypolyglutamate synthase that, in turn, binds to dihydrofolate reductase and inhibits its activity. Methotrexate-polyglutamate is degraded intracellularly by gamma-glutamyl hydrolase.
Potent inhibitor of dihydrofolate reductase and agent for antitumor studies. Use to inhibit dihydrofolate reductase in DHFR-based protein expression systems. Also effective in treatment of pyrimethamine-resistant Plasmodium vivax malaria parasites. Potent inhibitor of dihydrofolate reductase and agent for antitumor studies. Use to inhibit dihydrofolate reductase in DHFR-based protein expression systems. Also shows immunosuppressive effects in, e.g., rheumatoid arthritis.
Methotrexate is an allosteric inhibititor of dihydrofolate reductase (DHFR), the enzyme that catalyzes the conversion of dihydrofolate to tetrahydrofolate. Since tetrahydrolfolate is required for purine and pyrimidine synthesis, methotrexate treatment results in the inhibition of DNA and RNA synthesis.
Soluble in alkaline solutions with decomposition. Insoluble in water, ethanol, chloroform and ether.